Quest Diagnostics Cash Flow from Investing Activities 2010-2024 | DGX

Quest Diagnostics annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
  • Quest Diagnostics cash flow from investing activities for the quarter ending December 31, 2024 was $-2.548B, a 140.15% increase year-over-year.
  • Quest Diagnostics cash flow from investing activities for the twelve months ending December 31, 2024 was $-5.220B, a 73.65% increase year-over-year.
  • Quest Diagnostics annual cash flow from investing activities for 2024 was $-2.548B, a 140.15% increase from 2023.
  • Quest Diagnostics annual cash flow from investing activities for 2023 was $-1.061B, a 95.4% increase from 2022.
  • Quest Diagnostics annual cash flow from investing activities for 2022 was $-0.543B, a 2685.71% decline from 2021.
Quest Diagnostics Annual Cash Flow Investing
(Millions of US $)
2024 $-2,548
2023 $-1,061
2022 $-543
2021 $21
2020 $-772
2019 $-411
2018 $-801
2017 $-830
2016 $-127
2015 $-362
2014 $-1,025
2013 $328
2012 $-217
2011 $-1,243
2010 $-217
2009 $-196
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $19.317B $9.872B
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $21.804B 0.00
DaVita (DVA) United States $11.363B 14.49
Encompass Health (EHC) United States $9.962B 22.32
Chemed (CHE) United States $8.236B 25.31
Elanco Animal Health (ELAN) United States $5.492B 13.07
Option Care Health (OPCH) United States $5.459B 25.87
RadNet (RDNT) United States $4.453B 98.62
Amedisys (AMED) United States $2.998B 21.34
LifeStance Health (LFST) United States $2.904B 0.00
Addus HomeCare (ADUS) United States $1.974B 22.91
Astrana Health (ASTH) United States $1.946B 26.61
U.S Physical Therapy (USPH) United States $1.298B 34.13
Pennant (PNTG) United States $0.864B 34.93
Aveanna Healthcare Holdings (AVAH) United States $0.799B 0.00
Atai Life Sciences (ATAI) Germany $0.305B 0.00
Bioqual (BIOQ) United States $0.054B 0.00
Daxor (DXR) United States $0.036B 0.00
Ontrak (OTRK) United States $0.007B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.004B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00
Psychemedics (PMD) United States $0.000B 0.00